Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients

Journal of the American Academy of Dermatology

Volumn 60, Issue 5, 2009, Pages 863-868

  Meier, Friedegund ^a   Guenova, Emmanuella ^a   Clasen, Stephan ^a   Eigentler, Thomas ^a   Forschner, Andrea ^a   Leiter, Ulrike ^a   Zielinski, Christina ^a   Knaudt, Björn ^a   Garbe, Claus ^a   Berneburg, Mark ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; LOW MOLECULAR WEIGHT HEPARIN; PACLITAXEL; RAPAMYCIN;

ADULT; ANAMNESIS; ARTICLE; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; LUNG EMBOLISM; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THROMBOSIS; TREATMENT RESPONSE;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MELANOMA; NEOPLASM METASTASIS; PACLITAXEL; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; SKIN NEOPLASMS;

EID: 64749104914     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.09.053     Document Type: Article

References (13)

1. Flaherty K.T. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 12 (2006) 2366-2370
2. Brognard J., Clark A.S., Ni Y., and Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61 (2001) 3986-3997
3. Tsurutani J., West K.A., Sayyah J., Gills J.J., and Dennis P.A. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 65 (2005) 8423-8432
4. Belyanskaya L.L., Hopkins-Donaldson S., Kurtz S., Simoes-Wust A.P., Yousefi S., Simon H.U., et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by surviving upregulation. Int J Cancer 117 (2005) 755-763
5. Ihle N.T., Williams R., Chow S., Chew W., Berggren M.I., Paine-Murrieta G., et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 3 (2004) 763-772
6. Weischer M., Rocken M., and Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion?. Exp Dermatol 16 (2007) 385-393
7. Bruns C.J., Koehl G.E., Guba M., Yezhelyev M., Steinbauer M., Seeliger H., et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 10 (2004) 2109-2119
8. Seeliger H., Guba M., Koehl G.E., Doenecke A., Steinbauer M., Bruns C.J., et al. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 10 (2004) 1843-1852
9. Mohi M.G., Boulton C., Gu T.L., Sternberg D.W., Neuberg D., Griffin J.D., et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A 101 (2004) 3130-3135
10. Margolin K., Longmate J., Baratta T., Synold T., Christensen S., Weber J., et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104 (2005) 1045-1048
11. Lasithiotakis K.G., Sinnberg T.W., Schittek B., Flaherty K.T., Kulms D., Maczey E., et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 128 (2008) 2013-2023
12. Thallinger C., Poeppl W., Pratscher B., Mayerhofer M., Valent P., Tappeiner G., et al. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology 79 (2007) 207-213
13. Thallinger C., Werzowa J., Poeppl W., Kovar F.M., Pratscher B., Valent P., et al. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. J Invest Dermatol 127 (2007) 2411-2417